Viewing Psoriasis as a Systemic Disease for Better Health Outcomes

JID Innovations (2021);1:100007 doi:10.1016/j.xjidi.2021.100007

TO THE EDITOR

Recent guidelines published by the National Psoriasis Foundation (NPF) and the American Academy of Dermatology (AAD) highlight the importance of addressing the systemic nature of psoriasis in clinical management of patients to optimize health outcomes (Elmets et al., 2021, 2019a, 2019b; Menter et al., 2020, 2019). Related guidelines have been issued by the American College of Rheumatology-NPF and the American Heart Association (Armstrong et al., 2017; Grundy et al., 2015). The comprehensive form of published clinical guidelines yields a voluminous document often difficult to distill into a resource bank, particularly for patients. To enhance the uptake of these long-awaited psoriatic disease guidelines, NPF and expert partners (see Acknowledgments section) created an infographic condensing these guidelines for clinicians and patients (Figure 1) (American Academy of Dermatology Association, 2020; Armstrong et al., 2017; Grundy et al., 2019; Kurd and Gelfand, 2009; Rachakonda et al., 2014). The graphical summary offers providers a tool for easy comprehension and prioritization of care and a resource for discussions with patients, a key highlight of the guidelines.

Psoriasis is an immune-mediated inflammatory disease affecting an estimated 8.3 million persons in the United States, including an estimated 600,000 persons living with undiagnosed psoriasis (Kurd and Gelfand, 2009; Rachakonda et al., 2014). Common signs and symptoms of psoriasis include raised, discolored, scaly patches on skin; persistent rash; itch; and swelling. These symptoms are the superficial manifestations of psoriasis, driven by a systemic inflammatory process. This process impacts the whole body, leading to higher rates of comorbidities that must be considered in the management of patients to optimize patient outcomes and QOL.

Comorbidities

The systemic inflammatory processes underlying psoriasis can manifest as, or contribute to the development of, comorbidities, including psoriatic arthritis (PsA), cardiovascular disease (CVD), metabolic syndrome, and mental illness. Psoriasis is a chronic disease prone to flares, making successful long-term management of patients difficult and increasing the burden of disease and the impact on QOL. Comorbid conditions further complicate effective disease management, inhibiting and even impairing patient outcomes. As per NPF-AAD guidelines, psoriasis and its related comorbidities are influenced by several lifestyle choices, such as smoking and alcohol consumption (Elmets et al., 2019a). Patients should be educated about the association between these behaviors and psoriasis severity and comorbid conditions and provided tools and resources to support behavioral change. Proactively screening patients for the presence of these comorbid conditions, referral to appropriate specialists, and initiating therapy as appropriate may decrease their impact on patient outcomes—especially in the instance of PsA (Elmets et al., 2019a).

CVD. Systemic inflammation promotes atherosclerosis, leading to an increased risk of CVD in individuals with psoriasis (Baumer et al., 2018; Mehta et al., 2010). Many studies demonstrate increased risk of heart attack, stroke, heart failure, and abnormal heart rhythm. Guidelines issued by the American Heart Association and the American College of Cardiologists identify psoriasis as a potent risk factor for CVD that warrants consideration of early statin initiation to prevent future CVD development (Grundy et al., 2019).

PsA. An estimated 30% of individuals with psoriasis develop a form of inflammatory arthritis known as PsA (Mease et al., 2013). PsA commonly involves enthesitis and dactylitis and lacks a definitive diagnostic test, complicating diagnosis and treatment. However, validated screening tools exist to screen patients (Mease et al., 2013). If left untreated, PsA can lead to functional impairment and disability in as little as 6 months, underscoring the importance of proactively screening patients (Haroon et al., 2015).

Metabolic disorders. Metabolic syndrome (obese waist, hypertension, high glucose, high triglycerides) refers to a group of metabolic-related diseases that increase risk of heart disease, stroke, and type 2 diabetes (Esser et al., 2014). Recent research has provided insight into the immunological components connecting psoriasis and metabolic syndrome (Patrick et al., 2020). Metabolic syndrome is associated with chronic systemic inflammation that impacts adipose tissue, liver (increased steatosis), and pancreas (increased insulin production owing to peripheral insulin resistance) (Esser et al., 2014). Thus, patients with psoriasis have a higher prevalence of metabolic syndrome than the general population, which also increases risk of atherosclerosis (Armstrong et al., 2013).

Mental illness. Individuals with psoriasis are more likely to have clinical...
depression than their peers (Dowlatshahi et al., 2014). Skin manifestations of psoriasis can contribute to patients feeling self-conscious and stigmatized, leading to altered social patterns, even avoiding social interactions. It is often assumed that these behavioral modifications facilitate the onset of depression. Yet, mental health disorders can both result from and contribute to progression of psoriasis. The presence of elevated proinflammatory cytokines suggest that psoriasis and mental health conditions (e.g., depression) may have overlapping biologic mechanisms (Koo et al., 2017).

**Treatment goals and therapies for psoriasis**

**Treatment goals.** Focusing treatment efforts on reducing body surface area (BSA) impacted and hence systemic inflammation is important, especially when considering comorbidities and optimizing health outcomes. Recent consensus work conducted by the NPF Medical Board yielded treatment targets for individuals with psoriasis when initiating therapy (BSA ≤ 3%), 3 months after initiation (BSA ≤ 1%), and during therapy maintenance (BSA ≤ 1%) (Armstrong et al., 2017). Treatment plan selection should be based on several factors, including disease severity, health status, patient preference and response to previous therapies, and acknowledging the systemic nature of psoriasis (Kaushik and Lebwohl, 2019a, 2019b). For a comprehensive list of available treatments for psoriasis, see the AAD-NPF Joint Guidelines for topical treatments, phototherapy, oral systemics, and biologics (Elmets et al., 2021, 2019b; Menter et al., 2020, 2008).

**Topical treatments.** Topical treatments encompass a variety of medications applied to the skin. These treatments may slow or normalize excessive cell reproduction and reduce inflammation symptoms and are appropriate for individuals with mild psoriasis (BSA ≤ 3%) or in combination with another treatment type. Topical treatments may impact systemic inflammation by impacting immune cell populations but may minimally impact risk of inflammatory-related comorbidities compared with other treatments (e.g., CVD, metabolic syndrome) (Ahlehoff et al., 2015; Elmets et al., 2019a; Wu et al., 2012).

**Phototherapy.** Phototherapy exposes the skin to UV light at prescribed intervals for a predetermined length of time to alter cytokine expression and immune response to reduce psoriasis symptoms (Wong et al., 2013). Similar to topical treatments, the impact of phototherapy on the risk of heart attack, stroke, and other cardiovascular comorbidities is lower than the impact of systemic psoriasis treatments (Ahlehoff et al., 2015; Strober et al., 2018; Wu et al., 2018).

**Oral systemics.** Oral systemic treatments refer to a broad class of treatments used to manage psoriasis that work within the body to impact the immune system through suppression of inflammatory
response, either in part or as a whole (Menter et al., 2020). Effect of oral systemic treatments on comorbidity risk is varied, making awareness of patient risk profile important when selecting these treatments (Hsu and Lan, 2017).

**Biologics.** Biologics are a relatively new class of psoriasis treatments approved for individuals with moderate-to-severe psoriasis that target specific inflammatory pathways (Elmets et al., 2019a). Recent studies have shown salutary effects of biologic therapy on psoriasis-related comorbidities, such as PsA, metabolic disorders, CVD, and mental illness (Elmets et al., 2019a; Esser et al., 2014; Koo et al., 2017). Presence of risk factors or signs of comorbidities may influence the choice of a biologic therapy.

**Conclusion**

In conclusion, this letter and accompanying infographic provide a resource for providers to understand the systemic nature of psoriasis and comorbid disease and can serve to share this information with their patients and families. It is the hope that the information will be used to improve care and health outcomes and emphasize the importance of treating psoriasis as a whole-body disease.

**ORCIDs**

George C. Gondo: http://orcid.org/0000-0002-6468-0397
Samantha Koons: http://orcid.org/0000-0002-9293-8594
Claire Metcalf: http://orcid.org/0000-0001-9566-2653
Stacie J. Bell: http://orcid.org/0000-0002-9987-567X
Nehal N. Mehta: http://orcid.org/0000-0003-4939-5130

**AUTHOR CONTRIBUTIONS**

Conceptualization: GCG, SK, SJB, NNM; Data Curation: GCG; Formal Analysis: GCG; Investigation: GCG; Methodology: GCG; Project Administration: GCG; Supervision: SJB, NNM; Visualization: GCG, SK, CM, SJB, NNM; Writing - Original Draft Preparation: GCG, SK; Writing - Review and Editing: SJB, NNM

**ACKNOWLEDGMENTS**

We would like to acknowledge the National Psoriasis Foundation (Portland, OR) Scientific Advisory Committee, Research Committee, and Board of Directors for their role in the creation of this infographic. These groups include perspectives from leading dermatology and rheumatology experts, many with research and clinical experience related to comorbidities, patients, and advocates.

**CONFLICT OF INTEREST**

The authors state no conflict of interest.

**REFERENCES**

Ablett-O H, Skov L, Giilason G, Gniadecki R, Iversen L, Bryld LE, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015;29:1128–34.

American Academy of Dermatology Association. Psoriasis clinical guidelines. https://www.aad.org/member/clinical-quality/guidelines/psoriasis. (accessed November 14, 2020).

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68:654–62.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol 2017;76:290–8.

Baumer Y, Ng Q, Sanda GE, Dey AK, Teague HL, Sorokin AV, et al. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight 2018;3:e97779.

Dowlatahahi EA, Wakkee M, Arens LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014;134:1542–51.

Elmets CA, Korman NJ, Prater EF, Stoff B, Connor C, Armstrong AW, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432–70.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019a;80:1073–113.

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2019b;80:1445–86.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826–50.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029–72.

Patrick MT, Stuart PE, Zhang H, Zhao Q, Yin X, He K, et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis [e-pub ahead of print]. J Invest Dermatol 2020. https://doi.org/10.1016/j.jid.2020.11.025 (accessed November, 29, 2020).

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014;70:512–6.

Strober B, Goedherm M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, et al. Depressive symptoms, depression, and the effect
of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018;78:70–80.

Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg 2013;17:6–12.

Wu JJ, Joshi AA, Reddy SP, Batech M, Egeberg A, Ahlehoff O, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol 2018;32:1320–6.

Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis [published correction appears in Arch Dermatol 2013;149:158]. Arch Dermatol 2012;148:1244–50.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/